PortalPublikationenAnticoagulants affect matrix metalloproteinase 9 levels in b...

Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls

Standard

Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls. / Rababah, Munir; Worthmann, Hans; Deb-Chatterji, Milani; Tryc, Anita B; Ma, Yue Tao; El Bendary, Omnia M; Hecker, Hartmut; Goldbecker, Annemarie; Heeren, Meike; Brand, Korbinian; Weissenborn, Karin; Lichtinghagen, Ralf.

in: CLIN BIOCHEM, Jahrgang 45, Nr. 6, 04.2012, S. 483-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rababah, M, Worthmann, H, Deb-Chatterji, M, Tryc, AB, Ma, YT, El Bendary, OM, Hecker, H, Goldbecker, A, Heeren, M, Brand, K, Weissenborn, K & Lichtinghagen, R 2012, 'Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls', CLIN BIOCHEM, Jg. 45, Nr. 6, S. 483-9. https://doi.org/10.1016/j.clinbiochem.2012.01.028

APA

Rababah, M., Worthmann, H., Deb-Chatterji, M., Tryc, A. B., Ma, Y. T., El Bendary, O. M., Hecker, H., Goldbecker, A., Heeren, M., Brand, K., Weissenborn, K., & Lichtinghagen, R. (2012). Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls. CLIN BIOCHEM, 45(6), 483-9. https://doi.org/10.1016/j.clinbiochem.2012.01.028

Vancouver

Rababah M, Worthmann H, Deb-Chatterji M, Tryc AB, Ma YT, El Bendary OM et al. Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls. CLIN BIOCHEM. 2012 Apr;45(6):483-9. https://doi.org/10.1016/j.clinbiochem.2012.01.028

Bibtex

@article{56253ba7870345889fa51de149ce4cb7,
title = "Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls",
abstract = "OBJECTIVES: Matrix metalloproteinase-9 (MMP-9) represents a promising marker for acute stroke management. In clinical studies MMP-9 has been quantified by ELISA using differing protocols. We aimed to establish a valid protocol by evaluation of preanalytics.DESIGN AND METHODS: Blood from stroke patients (n=28) and healthy controls (n=28) was drawn into tubes containing different anticoagulants (EDTA, citrate, lithium-heparin (heparin) and heparin with proteinase inhibitors) and processed after 0, 60 and 240 min. MMP-9 plasma protein and mRNA from mononuclear leukocytes were determined.RESULTS: In regard to anticoagulants used, samples showed different MMP-9 protein baseline values and kinetics. Stable MMP-9 protein concentrations were only measured from EDTA samples. Particularly in samples with proteinase inhibitors protein and mRNA concentrations increased over time. Kinetics did not differ between patients and controls.CONCLUSIONS: Preanalytics plays a key role for determination of MMP-9. EDTA seems to be a valid anticoagulant for MMP-9 protein measurement.",
keywords = "Adult, Aged, Aged, 80 and over, Anticoagulants, Artifacts, Blood Chemical Analysis, Case-Control Studies, Citric Acid, Enzyme Stability, Female, Heparin, Humans, Leukocytes, Mononuclear, Male, Matrix Metalloproteinase 9, Middle Aged, RNA, Messenger, Statistics, Nonparametric, Stroke, Transcription, Genetic, Journal Article",
author = "Munir Rababah and Hans Worthmann and Milani Deb-Chatterji and Tryc, {Anita B} and Ma, {Yue Tao} and {El Bendary}, {Omnia M} and Hartmut Hecker and Annemarie Goldbecker and Meike Heeren and Korbinian Brand and Karin Weissenborn and Ralf Lichtinghagen",
note = "Copyright {\textcopyright} 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.",
year = "2012",
month = apr,
doi = "10.1016/j.clinbiochem.2012.01.028",
language = "English",
volume = "45",
pages = "483--9",
journal = "CLIN BIOCHEM",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls

AU - Rababah, Munir

AU - Worthmann, Hans

AU - Deb-Chatterji, Milani

AU - Tryc, Anita B

AU - Ma, Yue Tao

AU - El Bendary, Omnia M

AU - Hecker, Hartmut

AU - Goldbecker, Annemarie

AU - Heeren, Meike

AU - Brand, Korbinian

AU - Weissenborn, Karin

AU - Lichtinghagen, Ralf

N1 - Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

PY - 2012/4

Y1 - 2012/4

N2 - OBJECTIVES: Matrix metalloproteinase-9 (MMP-9) represents a promising marker for acute stroke management. In clinical studies MMP-9 has been quantified by ELISA using differing protocols. We aimed to establish a valid protocol by evaluation of preanalytics.DESIGN AND METHODS: Blood from stroke patients (n=28) and healthy controls (n=28) was drawn into tubes containing different anticoagulants (EDTA, citrate, lithium-heparin (heparin) and heparin with proteinase inhibitors) and processed after 0, 60 and 240 min. MMP-9 plasma protein and mRNA from mononuclear leukocytes were determined.RESULTS: In regard to anticoagulants used, samples showed different MMP-9 protein baseline values and kinetics. Stable MMP-9 protein concentrations were only measured from EDTA samples. Particularly in samples with proteinase inhibitors protein and mRNA concentrations increased over time. Kinetics did not differ between patients and controls.CONCLUSIONS: Preanalytics plays a key role for determination of MMP-9. EDTA seems to be a valid anticoagulant for MMP-9 protein measurement.

AB - OBJECTIVES: Matrix metalloproteinase-9 (MMP-9) represents a promising marker for acute stroke management. In clinical studies MMP-9 has been quantified by ELISA using differing protocols. We aimed to establish a valid protocol by evaluation of preanalytics.DESIGN AND METHODS: Blood from stroke patients (n=28) and healthy controls (n=28) was drawn into tubes containing different anticoagulants (EDTA, citrate, lithium-heparin (heparin) and heparin with proteinase inhibitors) and processed after 0, 60 and 240 min. MMP-9 plasma protein and mRNA from mononuclear leukocytes were determined.RESULTS: In regard to anticoagulants used, samples showed different MMP-9 protein baseline values and kinetics. Stable MMP-9 protein concentrations were only measured from EDTA samples. Particularly in samples with proteinase inhibitors protein and mRNA concentrations increased over time. Kinetics did not differ between patients and controls.CONCLUSIONS: Preanalytics plays a key role for determination of MMP-9. EDTA seems to be a valid anticoagulant for MMP-9 protein measurement.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Anticoagulants

KW - Artifacts

KW - Blood Chemical Analysis

KW - Case-Control Studies

KW - Citric Acid

KW - Enzyme Stability

KW - Female

KW - Heparin

KW - Humans

KW - Leukocytes, Mononuclear

KW - Male

KW - Matrix Metalloproteinase 9

KW - Middle Aged

KW - RNA, Messenger

KW - Statistics, Nonparametric

KW - Stroke

KW - Transcription, Genetic

KW - Journal Article

U2 - 10.1016/j.clinbiochem.2012.01.028

DO - 10.1016/j.clinbiochem.2012.01.028

M3 - SCORING: Journal article

C2 - 22342361

VL - 45

SP - 483

EP - 489

JO - CLIN BIOCHEM

JF - CLIN BIOCHEM

SN - 0009-9120

IS - 6

ER -